Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) ...

Merck's Keytruda wins EU approval for a new injectable form, offering greater treatment options for adults. Read more here.

Rahway, New Jersey Thursday, November 20, 2025, 14:00 Hrs [IST] ...

Merck & Co, known as MSD outside of the USA and Canada, today announced that the European Commission (EC) has approved a new ...

This is the first and only subcutaneous immune checkpoint inhibitor in Europe that a health care provider can administer in ...

Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval ...

Industry analyst GlobalData has highlighted the significance of US pharma major Merck's (NYSE: MRK) plan to buy US biotech ...

Keytruda showed a significant survival benefit over Tecentriq and Opdivo in older adults with metastatic NSCLC, with a 33% ...

Libtayo plus chemotherapy is potentially more cost-effective than Keytruda plus chemotherapy for advanced NSCLC, offering lower costs and higher QALYs. The study's model, based on clinical trial data, ...

Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a ...

Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in ...

Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell ...